Biogen Idec has expanded its partnership with Samsung Bioepis after exercising its right to commercialise anti-TNF biosimilar product candidates in Europe.
The companies will work together to sell biosimilars for widely-used therapies to treat conditions such as rheumatoid arthritis and Crohn's disease in the EU, where a strong market for biosimilars and a defined regulatory pathway already exist.
This comes after Biogen Idec's new multiple sclerosis therapy Tecfidera was designated as a new active substance by the European Medicines Agency's Committee for Medicinal Products for Human Use last month.
Samsung Bioepis is a joint venture created by Samsung Biologics and Biogen Idec with the aim of developing affordable and high-quality biopharmaceutical and biosimilar products.
READ MORE
